SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-21-020162
Filing Date
2021-04-05
Accepted
2021-04-05 17:15:46
Documents
40
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20201231.htm   iXBRL 10-Q 662171
7 EXHIBITS 31.1 ex311_1.htm EX-31.1 16610
8 EXHIBITS 32.1 ex321_2.htm EX-32.1 5093
  Complete submission text file 0001213900-21-020162.txt   4055667

Data Files

Seq Description Document Type Size
2 SCHEMA rasp-20201231.xsd EX-101.SCH 53570
3 CALCULATION rasp-20201231_cal.xml EX-101.CAL 45249
4 DEFINITION rasp-20201231_def.xml EX-101.DEF 268377
5 LABEL rasp-20201231_lab.xml EX-101.LAB 835008
6 PRESENTATION rasp-20201231_pre.xml EX-101.PRE 420155
9 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20201231_htm.xml XML 305409
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 21806535
SIC: 2834 Pharmaceutical Preparations